A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector VV-14295 Administered Suprachoroidally With the Everads Injector In AdultS With GeographIc Atrophy Secondary to Age-related Macular DegeneratiON (the VISION Study)

Inclusion Criteria: * Participant must be between 55 to 80 years of age (inclusive), at the time of signing the informed consent form. * Body mass index (BMI) of 19 to 34 kg/m2 (inclusive). * Must agree to use reliable contraception for at least 12 months after administration of VV-14295. A female participant is eligible to participate if she is not pregnant and not breastfeeding. * The GA lesion must meet certain criteria as assessed by a central reading center's assessment of imaging at Screening. * Adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the co…